Toshihiro Higashikawa, Tomohiko Ito, Takurou Mizuno, Keiichiro Ishigami, Kengo Kuroki, Naoto Maekawa, Daisuke Usuda, Toshihide Izumida, Shinya Yamada, Ryusho Sangen, Kazu Hamada, Jun Kiyosawa, Atsushi Saito, Masaharu Iguchi, Yuji Kasamaki, Takeshi Nakahashi, Akihiro Fukuda, Hitoshi Saito, Tsugiyasu Kanda, Masashi Okuro
The sodium glucose transporter 2 (SGLT2) inhibitor tofogliflozin is a glucose-lowering drug that causes the excretion of surplus glucose by inhibiting SGLT2. Because of tofogliflozin's osmotic diuresis mechanism, patients' serum electrolytes, body fluid levels, and cardiac function must be monitored. We retrospectively analyzed the cases of 64 elderly Japanese patients with type 2 diabetes mellitus (T2DM) who received tofogliflozin for 3 months. Their HbA1c, serum electrolytes (sodium, potassium, chloride), hematocrit, brain natriuretic peptide (cardiac volume load marker) and renin and aldosterone (RAA; an index of regulatory hormones involved in body fluid retention) were continuously monitored during the investigation period...
December 2022: Acta Medica Okayama